"name","description","label","instanceType","uuid:ID","id","rationale"
"Study Design 1","The main design for the study","","StudyDesign","f32f1970-ca06-4774-9f3f-b9456ccb7cd0","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
